IGM Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 224
- Market Cap
- $606.8M
- Website
- http://www.igmbio.com
- Introduction
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
- Conditions
- Idiopathic Inflammatory MyopathiesInflammatory Myopathies
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT06524687
- Locations
- 🇺🇸
Standford University, Palo Alto, California, United States
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
- Conditions
- Relapsed/Refractory Non-Hodgkin Lymphomas
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- IGM Biosciences, Inc.
- Registration Number
- NCT06331832
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇰🇷Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
🇪🇸START-Madrid Centro Integral Oncologico Clara Campal, Madrid, Spain
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
- Conditions
- Rheumatoid ArthritisArthritis, RheumatoidArthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT06087406
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC, Glendale, Arizona, United States
🇺🇸Triwest Research Associates, San Diego, California, United States
🇺🇸East Bay Rheumatology Medical Group, San Leandro, California, United States
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus ErythematosusLupus Erythematosus
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT06041568
- Locations
- 🇺🇸
TriWest Research Associates, San Diego, California, United States
🇺🇸East Bay Rheumatology, San Leandro, California, United States
🇺🇸Omega Research, DeBary, DeBary, Florida, United States
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05908396
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05702424
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸Carolina Biooncology Institute, Huntersville, North Carolina, United States
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05184218
- Locations
- 🇿🇦
Farmovs, Bloemfontein, Free State, South Africa
Evaluation of IGM-6268 in Healthy Volunteers
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05160402
- Locations
- 🇺🇸
Aventiv Research, Columbus, Ohio, United States
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
- Conditions
- Acute Myeloid LeukemiaSarcomaChondrosarcomaChronic Lymphocytic LeukemiaColorectal CancerSolid TumorNon Hodgkin LymphomaSmall Lymphocytic Lymphoma
- Interventions
- Drug: Aplitabart (IGM-8444)Drug: FOLFIRI
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT04553692
- Locations
- 🇺🇸
Mayo Clinic, Minneapolis, Minnesota, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Cancer and Blood Specialty Clinic (CBSC), Los Alamitos, California, United States
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin LymphomaFollicular LymphomaDLBCLMarginal Zone LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04082936
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States